Brought to you by 
Prosidion acquires Probiodrug's DP-IV platform and assets
30 Jan 2023
Executive Summary
OSI Pharmaceuticals' majority owned subsidiary Prosidion Ltd. (small-molecule therapeutics for diabetes and obesity) is purchasing Probiodrug AG's dipeptidyl peptidase IV (DP-IV) technology platform and related intellectual property for €29mm ($35mm) in cash.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Prosidion acquires Probiodrug's DP-IV platform and assets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice